Clinical Trials Logo
  1. Home
  2. High-grade B-cell Lymphoma
  3. NCT01809600

Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults — RBL  

High-grade B-cell Lymphoma Clinical Trial

Official title:
Rituximab-Containing Immunochemotherapy for Burkitt's Lymphoma (BL) and High-Grade B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL

Clinical Trial Summary

This retrospective study is aimed at evaluating the safety and efficacy of rituximab-containing immunochemotherapy in adult patients with Burkitt's lymphoma (BL) or high-grade B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and BL.

Clinical Trial Description

Inclusion criteria

1. pathologically confirmed BL or BL-U by World Health Organization 2008 criteria

2. age >20 yrs

3. received rituximab+chemotherapy as first-line treatment

4. with measurable or evaluable lesion

5. with complete set of clinical and laboratory data for the analysis ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01809600
Study type Observational
Source Gachon University Gil Medical Center
Contact
Status Completed
Phase N/A
Start date February 2013
Completion date March 2014
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04555811 - FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL Phase 1
Recruiting NCT04226937 - DLBCL Interim Response Evaluation for Customised Therapy
Not yet recruiting NCT05834426 - Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers
Recruiting NCT06026319 - CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma Phase 1
Not yet recruiting NCT06093841 - Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL Phase 2
Recruiting NCT04300998 - Study of CAR-T Therapy in Older Patients
Recruiting NCT04796857 - Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL Phase 1/Phase 2
Completed NCT04933617 - Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas Phase 1
Terminated NCT04358458 - First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas Phase 1/Phase 2
Recruiting NCT05621096 - Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma Phase 1
Not yet recruiting NCT06287398 - Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL Phase 2
Recruiting NCT04594642 - A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Phase 1
Recruiting NCT04836507 - Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients Phase 1/Phase 2
Terminated NCT04844086 - RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies Phase 1
Completed NCT04858568 - Immune Responses to COVID-19 Vaccination in Lymphoma Patients
Recruiting NCT04855253 - Study of E7777 Prior to Kymriah for R/R DLBCL Phase 1/Phase 2
Active, not recruiting NCT04914741 - A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) Phase 1/Phase 2
Not yet recruiting NCT06343311 - T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Phase 1/Phase 2
Active, not recruiting NCT04067414 - Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma Phase 1
Terminated NCT03132584 - Cyclophosphamide and Alemtuzumab In Lymphoma Phase 1